Research Paper

PAIN

OPEN

Rare $Na_V1.7$ variants associated with painful diabetic peripheral neuropathy

Iulia Blesneac[a], Andreas C. Themistocleous[a,b], Carl Fratter[c], Linus J. Conrad[d], Juan D. Ramirez[a], James J. Cox[e], Solomon Tesfaye[f], Pallai R. Shillo[f], Andrew S.C. Rice[g], Stephen J. Tucker[d,h], David L.H. Bennett[a,h,*]

Abstract

Diabetic peripheral neuropathy (DPN) is a common disabling complication of diabetes. Almost half of the patients with DPN develop neuropathic pain (NeuP) for which current analgesic treatments are inadequate. Understanding the role of genetic variability in the development of painful DPN is needed for improved understanding of pain pathogenesis for better patient stratification in clinical trials and to target therapy more appropriately. Here, we examined the relationship between variants in the voltage-gated sodium channel $Na_V1.7$ and NeuP in a deeply phenotyped cohort of patients with DPN. Although no rare variants were found in 78 participants with painless DPN, we identified 12 rare $Na_V1.7$ variants in 10 (out of 111) study participants with painful DPN. Five of these variants had previously been described in the context of other NeuP disorders and 7 have not previously been linked to NeuP. Those patients with rare variants reported more severe pain and greater sensitivity to pressure stimuli on quantitative sensory testing. Electrophysiological characterization of 2 of the novel variants (M1852T and T1596I) demonstrated that gain of function changes as a consequence of markedly impaired channel fast inactivation. Using a structural model of $Na_V1.7$, we were also able to provide further insight into the structural mechanisms underlying fast inactivation and the role of the C-terminal domain in this process. Our observations suggest that rare $Na_V1.7$ variants contribute to the development NeuP in patients with DPN. Their identification should aid understanding of sensory phenotype, patient stratification, and help target treatments effectively.

Keywords: Diabetic peripheral neuropathy, Neuropathic pain, Voltage-gated sodium channel $Na_V1.7$, Genetics, Electrophysiology

1. Introduction

Diabetes mellitus is a common chronic disease that affects 415 million people worldwide (IDF Diabetic Atlas), and the numbers are expected to rise arriving to 642 million by 2040. Diabetic peripheral neuropathy (DPN) is one of the most frequent long-term complications of diabetes affecting 30% to 50% of patients and is associated with significant morbidity.[25,57] Up to 50% of the patients suffering from DPN will develop neuropathic pain (NeuP), which is typically expressed as spontaneous pain but, in a minority, also includes evoked pain such as brush-evoked allodynia.[2,9,60] Painful DPN can have a major deleterious impact on the patients' quality of life, and unfortunately, the current first-line analgesics show modest efficacy and poor tolerability.[27] To develop new and better target existing therapies for painful DPN, we need to improve our understanding of NeuP pathophysiology and its individual variability in DPN.

Risk factors for the development of painful DPN include older age, poor glycaemic control, and more severe neuropathy. However, genetic factors have been relatively underexplored.[31] Here, we investigate the relationship between variants in the voltage-gated sodium channel $Na_V1.7$ and painful DPN.

The rationale for studying $Na_V1.7$ is that this voltage-gated sodium channel is expressed in nociceptors and amplifies subthreshold stimuli. It is therefore a key determinant of nociceptor excitability, and selective blockers of $Na_V1.7$ are under active development as novel analgesics (for review see Ref. 20). $Na_V1.7$ has been shown to be important in pathological pains states in humans.[6,62] Homozygous loss of function mutations in $Na_V1.7$ have been shown to cause congenital insensitivity to pain.[15] Conversely, heterozygous gain of function variants have been associated with a number of pain disorders including inherited erythromelalgia,[65] paroxysmal extreme pain disorder (PEPD),[26] and idiopathic small fibre neuropathy.[24] In addition to these rare disorders associated with high impact variants, single

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

[a] Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, [b] Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, [c] Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, The Churchill Hospital, Oxford, United Kingdom, [d] Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, United Kingdom, [e] Molecular Nociception Group, University College London, London, United Kingdom, [f] Diabetes Research Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, [g] Pain Research Group & Pain Medicine, Imperial College London, Chelsea and Westminster Hospital Campus, London, United Kingdom, [h] OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, United Kingdom

Corresponding author. Address: Neural Injury Group, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom. Tel. +44 (0) 1865 231512; fax +44 (0) 1865 234837. E-mail address: david.bennett@ndcn.ox.ac.uk (D. L.H. Bennett).

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.painjournalonline.com).

PAIN 159 (2018) 469–480

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

http://dx.doi.org/10.1097/j.pain.0000000000001116

nucleotide polymorphisms in $Na_V1.7$ may have a more subtle effect in modulating the risk and severity of pain in acquired pain disorders. An example is the gain of function R1150W variant in $Na_V1.7$, which was associated with an increased pain score in people with osteoarthritis, sciatica, phantom pain, lumbar discectomy, and pancreatitis.[46]

Painful DPN is one of the most common acquired NeuP states in which a metabolic insult interacts with genotype; whether $Na_V1.7$ variants are associated with NeuP in DPN has not been established. We have therefore investigated whether common or rare $Na_V1.7$ variants are associated with NeuP in a cohort of patients with DPN who have undergone detailed sensory phenotyping. Detailed sensory phenotyping enables patient stratification in a manner that will reflect the pathomechanisms and that may be predictive of treatment response.[4,5,18] Our aims were therefore to determine whether $Na_V1.7$ variants were related to NeuP, to determine the functional effects of such $Na_V1.7$ variants, and whether $Na_V1.7$ variants could be related to somatosensory phenotype to improve patient stratification.

2. Materials and methods

2.1. Study participants and clinical phenotyping

Study participants were recruited as part of the Pain in Neuropathy Study.[59] Pain in Neuropathy Study is an observational cross-sectional multicentre study approved by the National Research Ethics Service of the United Kingdom (No.: 10/H0706/35). All study participants signed written consent before enrolment. A detailed description of the study can be found elsewhere[59] and will only briefly be described. Participants underwent a structured neurological examination, nerve conduction studies, skin biopsy for intraepidermal nerve fibre density (IENFD) assessment, and a detailed quantitative sensory testing (QST) assessment. Further drug, laboratory, and clinical investigation data were retrieved from the clinical medical records. The data included nerve conduction study data and the most recent routine haematological and biochemical parameters, including HbA1c. Basic clinical parameters, such as weight, height, and blood pressures, were measured for each participant. Only study participants who had diabetes mellitus with evidence of clinical length–dependant neuropathy[57] confirmed by abnormalities on either nerve conduction studies or IENFD would proceed to sequencing of their DNA (Figure S1, available online as supplemental digital content at http://links.lww.com/PAIN/A509).

A comprehensive structured upper and lower limb neurological examination was performed to detect clinical signs of peripheral neuropathy.[36,42] The examination included assessment of temperature, light touch and pinprick sensation, joint position proprioception, vibration perception, deep tendon reflexes, muscle bulk, and motor power. The clinical findings were quantified with the Toronto clinical scoring system[10] and Medical Research Council (MRC) sensory sum score.

Nerve conduction tests were performed with an ADVANCE system (Neurometrix, Waltham, MA) and used conventional reusable electrodes. Sural sensory and peroneal motor nerve conduction studies were performed.[11] Our protocol was in line with those recommended by the American Academy of Neurology and American Association of Electrodiagnostic Medicine.[21]

The determination of IENFD from skin biopsy samples is a validated and sensitive diagnostic tool for the assessment of small fibre neuropathies, including diabetic neuropathy.[37] Biopsy samples were taken in accordance with the consensus document produced by the European Federation of Neurological Societies and the Peripheral Nerve Society Guideline on the utilisation of skin biopsy samples in the diagnosis of peripheral neuropathies.[37]

Quantitative sensory testing to determine somatosensory phenotypes was performed according to a previously published protocol of the German research network of NeuP (DFNS).[48] Quantitative sensory testing is a measure of sensory perception to a given stimulus. This test can show abnormalities in sensory function. Quantitative sensory testing data were entered into the data analysis system, Equista, provided by the DFNS. Equista transformed the raw QST data into *z*-scores, thus normalising for age, sex, and the body location of testing.[40,49] A *z*-score of zero is equal to the mean of the population. A score of greater or less than 2 SDs from the mean indicates gain of function or loss of function, respectively.

Orthostatic hypotension, as a marker of autonomic neuropathy, was assessed by measuring lying and standing blood pressure in accordance with established protocols.[1] Orthostatic hypotension was defined as either a 20-mm Hg reduction in systolic or a 10-mm Hg reduction in diastolic blood pressure. The Survey of Autonomic Symptoms[68] is an instrument that measures the presence and impact of autonomic symptoms. It consists of 12 questions that are individually rated on a 6-point rating scale from 0 (not at all) to 5 (a lot).

2.2. Definition of neuropathic pain

Only study participants with a confirmed DPN proceeded to NeuP subtyping (Figure S1, available online as supplemental digital content at http://links.lww.com/PAIN/A509). The presence of chronic NeuP caused by peripheral DPN was determined at the time of the clinical assessment and was in line with the IASP definition of NeuP ie, "pain caused by a lesion or disease of the somatosensory system." The IASP/NeuPSIG grading system was used to grade the NeuP.[28] Thus, participants were divided in to those with NeuP (painful DPN) and those without NeuP (painless DPN). Only study participants with chronic NeuP present for at least 3 months were included in the NeuP group. Study participants with non-NeuP in the extremities, such as musculoskeletal pain of the ankle, were included in the non-NeuP group.

The assessment of each study participant therefore satisfied the following criteria:

(1) Pain with a distinct neuroanatomically plausible distribution ie, pain symmetrically distributed in the extremities—completion of body map and clinical history.
(2) A history suggestive of a relevant lesion or disease affecting the peripheral or central somatosensory system—diagnosis of diabetes mellitus and a history of neuropathy symptoms including decreased sensation, positive sensory symptoms eg, burning, aching pain mainly in the toes, feet, or legs.
(3) Demonstration of distinct neuroanatomically plausible distribution of NeuP—presence of clinical signs of peripheral neuropathy ie, decreased distal sensation or decreased/absent ankle reflexes.
(4) Demonstration of the relevant lesion or disease by at least 1 confirmatory test—abnormality on either the nerve conduction tests or IENFD.

Pain severity was calculated either from a pain intensity diary or the average pain over the past 24 hours. The pain intensity diary was completed over 7 days, with participants recording pain at 9 AM and 9 PM daily on an 11-point scale, with 0 being no pain and 10 the worst pain imaginable. The severity of NeuP from the pain diary was calculated as the mean of the pain scores obtained

from the 7-day pain intensity diary. Further quantification of the NeuP was calculated with the Douleur neuropathique en 4 (DN4) questionnaire.[7] The DN4 is a screening tool for NeuP, with a score greater than 4 highly suggestive of NeuP. Study participants completed a body map that highlighted the distribution of any pain experienced. Brief Pain Inventory pain interference and pain severity subscales[56] were used to assess any type of pain (non-neuropathic and neuropathic) that study participants experienced and the impact of the pain on activities of daily living. Brief Pain Inventory pain relief quantifies the relief of pain, as a percentage, that participants enjoyed after administration of an analgesic. Neuropathic Pain Symptom Inventory,[8] a self-administered questionnaire, evaluated NeuP symptoms including evoked pain, spontaneous pain, paroxysmal pain, and dysaesthesias.

2.3. Sequencing of $Na_V1.7$

Sequencing of the coding regions of *SCN9A* was undertaken by next-generation sequencing using the HaloPlex Target Enrichment System (Agilent Technologies, Santa Clara, CA) and MiSeq Sequencing Platform (Illumina, Inc, San Diego, CA). Sequence analysis was performed using an in-house bioinformatics pipeline utilising Burrows-Wheeler Alignment tool[38] for mapping to the human genome and Platypus[47] for variant calling. Variants were annotated against reference sequences NM_002977.3 (mRNA) and NP_002968.1 (protein). Any variant that was present both at >1% allele frequency in the Exome Variant Database (http://evs.gs.washington.edu/EVS) and not previously reported in the literature in association with painful neuropathy was considered unlikely to be pathogenic and was not investigated further. Variants of potential interest were confirmed by Sanger sequencing by capillary electrophoresis using a 3730 DNA analyzer (Applied Biosystems, Foster City, CA).

2.4. Plasmids and site-directed mutagenesis

Human $Na_V1.7$ cDNA was cloned into a modified pcDNA3 expression vector containing downstream IRES and dsRED2 sequences (*SCN9A*-IRES-DsRED) (Cox, 2006). Human β1 and β2 subunits were cloned into pIRES2-AcGFP (SCN1B-IRES-SCN2B-IRES-eGFP).[15] Mutations were introduced using QuikChange II XL site-directed mutagenesis kit (Agilent).

2.5. HEK293T cell culture and transfection

Human embryonic kidney HEK-293T cells were grown in Dulbecco modified Eagle's culture medium (DMEM/F-12, ThermoFisher Scientific, United Kingdom) containing 10% fetal bovine serum and maintained under standard conditions at 37°C in a humidified atmosphere containing 5% Co_2. Cells were transfected using the jetPEI transfection reagent (Polyplus-transfection Inc, France), with either wild type (WT) or mutant $Na_V1.7$ channel combined with β1 and β2 subunits (2:1 ratio). Cells were used 36 to 72 hours after transfection.

2.6. Electrophysiology

Whole-cell patch clamp recordings were conducted at room temperature using an Axopatch 200B amplifier, the Digidata 1550B Low Noise Data Acquisition System, and pClamp10.6 software (Molecular Devices). Data were filtered at 5 kHz and digitized at 20 kHz. Capacity transients were cancelled and series resistance compensated at 70% to 90% in all experiments. Voltage clamp experiments were performed on transfected HEK293T cells. The extracellular solutions contained (in millimolar) the following: 140 NaCl, 3 KCl, 1 $CaCl_2$, 1 $MgCl_2$, 10 HEPES, and pH 7.3 with NaOH (adjusted to 320 mOsm/L with glucose). Patch pipettes were filled with an internal solution containing (in millimolar) 140 CsF, 10 NaCl, 1 EGTA, 10 HEPES, and pH 7.3 with CsOH (adjusted to 310 mOsm/L with glucose) and had a typical resistance of 2 to 3 MΩ. Leak currents were subtracted using a P/5 protocol, applied after the test pulse. A holding potential of −100 mV and an intersweep interval of 10 seconds were used for all the protocols. Current voltage curves (I-V curves) were fitted using a combined Boltzmann and linear ohmic relationship: $I/I_{max} = G_{max}(V_m - E_{rev})/(1 + \exp^{(V_{1/2} - Vm)/k})$. Normalized conductance–voltage curves (activation curves) were fitted with a Boltzmann equation $G/G_{max} = 1/(1 + \exp^{(V_{1/2} - Vm)/k})$, where G was calculated as follows: $G = I/(V_m - E_{rev})$. Similarly, the steady-state fast inactivation curves were fitted with $I/I_{max} = 1/(1 + \exp^{-(V_{1/2} - V_m)/k})$ and the steady-state slow inactivation curves with $I/I_{max} = R_{in} + (1 - R)/(1 + \exp^{-(V_{1/2} - V_m)/k})$. In all the equations, $V_{1/2}$ represents the half activation and, respectively, half inactivation potential; V_m is the membrane potential, E_{rev} the reversal potential, k the slope factor, G the conductance, and I the current at a given V_m; G_{max} and I_{max} are the maximum conductance and current, respectively; R_{in} is the fraction of channels that are resistant to slow inactivation.

2.7. Structural modeling

The sequences of human Na_V channels were aligned to the known structures of the cockroach Na_V homologue Na_VPaS[52] and the $Na_V1.5$ C-terminal domain[61] using the structural alignment tool EXPRESSO.[3,19,43–45]

The alignment was manually edited and prepared for input into the modeller (version 9.18)[41,51,63] by matching the sequence of the structured templates exactly and by removing the sequences of insertions. Residues 1 to 34, 421 to 722 (1-2 intersubunit linker), and 974 to 1168 (2-3 inter-subunit linker) were deleted and replaced by a chain break. Both the available structures were used to template the model building. Calmodulin and FGF13 from the C-terminal structure were included. We generated 100 candidate models and assessed them with modellers Inbuilt Discrete Optimized Protein Energy score.[53] Promising models were manually inspected and were found to show minimal variation.

2.8. Statistical analysis

SPSS Statistics Version 22 (IBM) and GraphPad Prism were used for statistical analysis. The QST *z*-scores were compared across the 3 groups with 1-way analysis of variance (least significant difference post hoc test). Quantitative sensory testing *z*-score data were expressed as mean ± 95% confidence interval. All other data were tested for normality with the D'Agostino–Pearson normality test and by visual inspection of their distribution. All other data were not normally distributed and reported as median with interquartile range. Data were compared between the 2 groups with Mann–Whitney *U* test. Categorical data were analysed with χ^2 test of association. Statistical significance was set at $P = 0.05$.

3. Results

3.1. Study participants selection

The Pain in Neuropathy Study has recently been described in detail.[59] This study includes a cohort of 191 study participants

with definite DPN ie, diabetes mellitus with evidence of clinical length–dependant neuropathy confirmed by abnormalities on either nerve conduction studies or IENFD (Figure S1, available online as supplemental digital content at http://links.lww.com/PAIN/A509). In 189 of these participants, DNA was available for analysis (these are the study participants described here). The 189 study participants with definite DPN were separated into 2 groups: (1) the painful DPN group comprised 111 participants with NeuP and (2) the painless DPN group comprised 78 participants without NeuP. The painful DPN group satisfied the definition of definite neuropathic as defined by the NeuPSIG/IASP grading system.[28]

As previously described there were no significant differences between the 2 groups in terms of age, sex, body mass index, blood pressure, type 2 diabetes prevalence, and the time since diabetes mellitus diagnosis (Table S1, available online as supplemental digital content at http://links.lww.com/PAIN/A508). The participants with painful DPN had a more severe DPN and had a poorer diabetic control than the study participants with painless DPN (Table S1, available online as supplemental digital content at http://links.lww.com/PAIN/A508).

3.2. Identification of $Na_V1.7$ variants

In both groups, we then screened for rare $Na_V1.7$ variants ie, missense variants present at less than 1% frequency in population databases (Exome Variant Database and/or Exome Aggregation Consortium) and variants previously reported in the literature to be associated with painful neuropathy. Sequencing of the *SCN9A* gene, encoding the $Na_V1.7$ channel, in the 111 study participants from the painful DPN group revealed the presence of 12 rare $Na_V1.7$ variants in 10 study participants (**Fig. 1** and **Table 1**). Five of these variants were previously described in the literature as being associated with pain disorders and having a gain of function effect on $Na_V1.7$: V991L/M932L (note that these variants are in complete linkage disequilibrium[24]); W1538R,[16] R185H,[30] and I739V.[29] A further variant, L1267V,[34] has been reported in a patient with painful neuropathy. However, it was stated that this variant did not confer hyperexcitability on DRG neurons and that this patient had an additional *SCN11A* variant (and so pathogenicity is uncertain). The other 6 variants (I564T, K655R, S802G, K1043N, T1596I, and M1852T) have never been described before in association with NeuP (**Table 1** and **Fig. 1**). Most of the identified variants were found only in single-study participants with the exception of R185H, which was found in 2 study participants (**Table 1**). Also, there was 1 patient who carried 4 rare $Na_V1.7$ variants V991L, M932L, W1538R, and K1043T. Interestingly and in contrast to the painful DPN group, no rare $Na_V1.7$ variants were found in the 78 study participants with painless DPN. We also screened for more common $Na_V1.7$ variants (ie, nonsynonymous substitution that has a frequency in population databases higher than 1%), including R1150W which was associated with an increased pain score in a previous study.[46] No statistically significant difference between the 2 groups could be noticed for these polymorphisms (Table S2, available online as supplemental digital content at http://links.lww.com/PAIN/A508).

3.3. Clinical description of the study participants carrying rare $Na_V1.7$ variants

We compared the clinical characteristics of the 10 study participants carrying the rare $Na_V1.7$ variants with the rest of the 101 study participants from the painful DPN group without the rare $Na_V1.7$ variants.

The age, sex proportion, body mass index, diabetic control (HbA1c), blood pressure, and type 2 diabetes prevalence were similar between the 2 groups (**Table 2**). The Toronto clinical scoring system and MRC sensory sum score were also not significantly different indicating that the severity of the neuropathy does not differ. However, the study participants carrying the rare $Na_V1.7$ variants had been diagnosed for a significantly shorter duration. Also, for 6 of the study participants carrying the rare $Na_V1.7$ variants, the onset of NeuP was at a similar time as the diagnosis of diabetes (**Table 1**). None of the study participants carrying a rare variant reported a family history of pain.

The study participants having painful DPN completed a set of questionnaires that quantified the severity of NeuP, the frequency and intensity of symptoms associated with NeuP, impact on the quality of life, and the frequency and impact of autonomic symptoms. The study participants carrying the rare $Na_V1.7$ variants reported higher scores across all questionnaires for pain intensity, and the difference reached a statistically significant value for the superficial spontaneous pain portion of the Neuropathic Pain Symptom Inventory (**Table 2**). Therefore, the study participants carrying the rare variants reported more severe burning pain than the remaining study participants with painful DPN. There were no differences regarding the other parameters.

To better assess the sensory phenotype and to have more insight into pathophysiological mechanisms, we also performed QST of the feet using the protocol developed by the DFNS.[48] Although most of the QST parameters were similar between the 2 groups, the *z*-score for pressure pain thresholds was significantly higher for the study participants with the rare $Na_V1.7$ variants (Figure S2, available online as supplemental digital content at http://links.lww.com/PAIN/A509). In addition, the *z*-score for pressure pain thresholds was significantly higher for the study participants carrying the rare $Na_V1.7$ variants when compared with the study participants with painless DPN (Figure S2, available online as supplemental digital content at http://links.lww.com/PAIN/A509). Study participants carrying the rare $Na_V1.7$ variants were therefore more sensitive to deep pressure and reported pain at lower pressures when applied to the arch of the foot.

3.4. Selection of $Na_V1.7$ variants for functional characterization

Among all the 6 $Na_V1.7$ variants not previously described in the literature, 2 were selected for further functional characterization: M1852T and T1596I. The selection was based on the following criteria: (1) position in important functional domains, (2) alteration of highly conserved residues, and (3) important amino acid exchange (high Grantham distance) (4) predicted as pathogenic by 4 different prediction algorithms (Align GVGD [http://agvgd.hci.utah.edu/], SIFT [http://sift.jcvi.org], MutationTaster [www.mutationtaster.org], and Polyphen-2 [http://genetics.bwh.harvard.edu/pph2/]).

The M1852T substitution changes a methionine with a polar amino acid to threonine. M1852 is situated in the C-terminal part of the protein and is highly conserved in every member of the Na_V family in humans (from $Na_V1.1$ to $Na_V1.9$) and also conserved across species (**Fig. 1A and B**). The variant was not present in the EVS database and was present at a very low frequency (%MAF 0.0016) in the ExAC database.

The T1596I substitution introduces an isoleucine, a hydrophobic amino acid, in place of a threonine. This amino acid sits at the top of the fourth helix of domain IV of the channel, an important helix for the voltage dependency of the channel. It is highly conserved among all the human Na_V isoforms and also

Table 1

Clinical descrption of the study participants with painful diabetic neuropathy carrying the rare $Na_V1.7$ variants.

Study participant	$Na_V1.7$ variant	MAF (ExAC)	PMID	Age	Sex	Ethnicity	Diabetes type	Age at diagnosis of diabetes	Age at onset of pain	Toronto clinical scoring system	24 hours pain	DN4	Analgesia	BPI pain relief	Postural blood pressure drop
1	R185H	0.33	Han et al., 2012, 22826602	48.4	m	Asian	2	31.7	44.7	7	4	4	Pregabalin	Not completed	No
2	R185H	0.33	Han et al., 2012, 22826602	64.9	m	White European	2	62.0	62.0	15	7	5	Pregabalin, duloxetine, capsaicin ointment, and co-codamol	40	Yes
3	I564T	0.0025	—	62.5	m	White European	2	51.2	52.2	13	9	7	Pregabalin and paracetamol	70	Yes
4	K655R	0.19	—	53.5	f	White European	2	40.2	51.5	12	9	8	Carbamazapine, codeine, ibuprofen, and paracetamol	100	No
5	I739V	0.39	Han et al., 2012, 22539570	75.7	m	White European	2	64.0	72.2	18	3	5	Gabapentin and co-codamol	100	No
6	S802G	0.29	—	41.4	m	Other	1	38.7	38.6	9	7	6	Gabapentin and tramadol	Not completed	No
7	M932L	2.95	Faber 2011, 21698661	49.8	m	White European	2	37.2	49.3	14	8	6	Oxycodone, naproxen, lorazepam, and duloxetine	50	No
	V991L	3.11	Faber 2011, 21698661												
	K1043N	0	—												
	W1538R	0.21	Cregg et al., 2013, 23292638												
8	L1267V	0.14	Hunag et al., 2014, 24776970	72.1	f	White European	2	68.8	64.9	12	6	9	None	Not applicable	No
9	T1596I	0.01	—	69.0	m	White European	2	61.3	61.3	12	7	6	Amitriptyline and tramadol	30	No
10	M1852T	0.0016	—	59.5	f	White European	2	55.6	56.6	11	7	7	Pregabalin and duloxetine	20	No

The 24-hour pain score was the average pain intensity over the preceding 24 hours rated on an 11-point Likert scale with 0 rated as "no pain" and 10 rated as the "worst pain imaginable." The DN4 score is a screening toll for neuropathic pain with a score greater than 4 suggestive of neuropathic pain. Postural blood pressure drop was used as a measure of autonomic dysfunction. Almost all participants were prescribed analgesics that included at least one drug recommended for the treatment of neuropathic pain. The BPI pain severity quantified the severity of pain, and the BPI pain relief quantified the analgesic effect enjoyed by the study participants.
BPI, Brief Pain Inventory; DN4, Douleur neuropathique 4; ExAC, Exome Aggregation Consortium; MAF, minor allele frequency; TCSS, Toronto clinical scoring system.

conserved among different species (evolutionary conservation) (**Fig. 1A and C**). The T1596I is present at a very low frequency in EVS and ExAC databases (%MAF 0.03 and 0.01, respectively).

Prediction programs like Align GVGD, SIFT MutationTaster, and PolyPhen-2 classified both M1852T and T1596I as "C65, likely to interfere with function," "deleterious," "disease causing," and "probably damaging," respectively.

3.5. Functional analysis of M1852T and T1596I variants

To investigate the effect that the M1852T and T1596I variants may have on the biophysical properties of the channel, we introduced these mutations into the cDNA of human $Na_V1.7$ and expressed the mutated channels in HEK293T cells. Representative whole-cell voltage clamp currents from transfected cells are shown in **Figure 2A**. The mutations had no significant effect on the voltage dependence of activation of the channel (**Fig. 2B and D**), but drastically changed the steady-state fast inactivation (**Fig. 2C**). A 14-mV depolarizing shift of the half inactivation potential ($V_{1/2}$) could be seen for the M1852T channels and a 15-mV positive shift for the T1596I channels. In addition, the mutant channels exhibited a significant increase in the slope factor for fast inactivation, the change being more prominent for the M1852T (9.1 ± 0.3 compared with 7.6 ± 0.3 for the T1596I and 5.6 ± 0.2 for the WT). The positive shift of the steady-state fast inactivation curve and the change in the slope factor led to



Figure 1. $Na_V1.7$ variants identified in study participants with painful diabetic peripheral neuropathy. (A) Schematic of $Na_V1.7$ channel topology. The variants previously reported in the literature as associated with painful neuropathy are represented with blue dots and the newly identified variants with red ones. (B) Sequence alignment of human $Na_V1.1$-$Na_V1.9$ channels and of $Na_V1.7$ channel in different species showing the conserved M1852 amino acid in red. (C) Sequence alignment of human $Na_V1.1$-$Na_V1.9$ channels and of $Na_V1.7$ channel in different species showing the conserved T1596 amino acid in red.

a marked increase in the overlap between the activation and the fast inactivation (**Fig. 2D**). This overlap predicts a larger window current for both M1852T and T1596I compared with the WT, signifying that a substantially larger fraction of channels would be active at a given resting membrane potential. No significant effect on the steady-state slow inactivation was found (**Fig. 2E**).

To further characterise the effects of the M1852T and T1596I variants on the inactivation properties of $Na_V1.7$ sodium channels, we analysed the open-state fast-inactivation kinetics. Single exponential fits of sodium current decay demonstrated that fast inactivation occurred at a considerable slower rate for both variants (**Fig. 2F**). For instance, at −25 mV, wild-type currents inactivated with a $\tau = 1.7 \pm 0.1$ ms, whereas M1852T and T1596I currents inactivated with a significantly increased τ (3.4 ± 0.3 ms, $P < 0.0001$ and 2.9 ± 0.5 ms, $P < 0.05$, respectively, compared with the WT). We also investigated the kinetics of the recovery from fast inactivation. Sodium channels containing the T1596I mutation recovered 3.6 times more quickly than the WT channels ($\tau = 28.7 \pm 6.8$ compared $\tau = 102.3 \pm 16.7$ for the WT, $P < 0.005$), whereas no significant change was found for the M1852T channels (**Fig. 2G**).

One of the ways that $Na_V1.7$ channels are believed to contribute to neuronal excitability is by generating slow depolarizations that boost subthreshold stimuli.[17] We therefore decided to examine inward currents produced by slow ramp depolarizations (**Fig. 2H**). An increase in the ramp current could be observed for both mutants, the M1852T mutation having a stronger effect.

3.6. Structural insights from the M1852T and T1596I variants

To gain further insights into the effect of these 2 variants, we constructed a structural model of the human $Na_V1.7$ channel. The model was based on the recently published structure of the eukaryotic Na_V homolog Na_VPS[52] and the structure of the human $Na_V1.5$ C-terminal domain.[61] Interestingly, this model shows that the C-terminal M1852T variant is located directly beneath and is in contact with the linker between domains III and IV (**Fig. 3A and B**). Fast inactivation of VGSCs is believed to occur by the movement of this "III-IV linker." The position of this variant at this interface between the C-terminal domain and the α-helical part of the III-IV linker is therefore entirely consistent with its functional effects. Intriguingly, a recent structure of the $Na_V1.4$ channel also

Table 2

Summary of variables that were compared between the study participants with rare $Na_V1.7$ variants and the rest of the painful diabetic peripheral neuropathy group.

	Painful diabetic neuropathy	
	With rare $Na_V1.7$ variants	**Without rare $Na_V1.7$ variant**
Number	10	101
Male	7 (70%)	70 (69.3%)
Age, y	61 (49.5-69.8)	67.6 (57.7-73)
HbA1c (%)	8.4 (7.6-9.5)	7.5 (6.8-8.9)
Type 2 diabetes	9 (90%)	90 (89.1%)
Duration of diabetes, y	**9.5 (3.2-12.8)**	**14.7 (8.5-22.7)***
BMI, kg/m^2	30.7 (28.5-36.7)	30.5 (26.4-36.1)
Standing BP	132/86 (115/64-149-88)	141/78 (128/67-153/83)
Lying BP	145/80 (120/66-156-94)	146/78 (135/71-156/85)
Orthostatic hypotension	2 (20%)	25 (26.9%)
MRC sensory sum score	10.5 (5-12.8)	6 (3-12)
TCSS total (adjusted)	11 (9.5-13.3)	11 (8-13.5)
TCSS symptoms score (adjusted)	3 (2-4)	3 (2-4)
TCSS sensory examination	4 (3-5)	3 (2-5)
TCSS examination	8.5 (7-9.3)	8 (5-10.5)
IENFD, fibres/mm	0.6 (0-1.4)	0.9 (0.3-1.6)
Pain over last 24 h	7 (5.5-8.3)	5.5 (4-8)
7 d pain diary	6.5 (4.9-7.2)	5 (2.9-6.8)
DN4	6 (5-7.3)	6 (4-7)
BPI pain interference	5.8 (7.9-2.8)	4.1 (2.5-6.1)
BPI pain severity	5.4 (3.8-7.1)	4.5 (2.5-6.3)
BPI pain relief (%)	50 (30-100)	40 (0-60)
NPSI total	5.2 (2.7-5.7)	3 (1.6-4.6)
NPSI deep spontaneous pain	3 (0-4.5)	1 (0-4)
NPSI superficial spontaneous pain	**7 (5-8.5)**	**4 (0-7)***
NPSI-evoked spontaneous pain	3 (1.2-4.9)	1.7 (0-4.3)
NPSI paraesthesiae	8 (3.5-8)	4.3 (1.9-8)
NPSI paroxysmal pain	4.5 (3.3-6.3)	3.5 (0.4-6.1)
Autonomic symptom score	5 (1.5-7)	4 (3-6)
Autonomic impact score	11 (6.5-17)	11 (6-17)

Data shown as median (interquartile range) and analysed by Mann–Whitney *U* test. Categorical data were analysed by Fischer exact test, and values and percentages are shown.
The variables that were significantly different between the two groups are shown in bold. *$P < 0.05$.
BP, blood pressure; BPI, Brief Pain Inventory; BMI, body mass index; DN4, Douleur neuropathique 4; IENFD, intra-epidermal nerve fibre assessment; MRC, Medical Research Council; NPSI, Neuropathic Pain Symptom Inventory; TCSS, Toronto clinical scoring system.

now reveals that this interaction is state dependent and does not occur in the open state.[64] It is therefore tempting to speculate that interactions at this interface stabilise the inactivated state and are reduced by the M1852T variant. Either way, this result now highlights how a dynamic interaction between these 2 parts of the channel is important for the control of fast inactivation.

The other variant, T1596I, is located at the top of the positively charged S4 helix within the voltage sensor of domain IV at the interface with the pore helices of domain 1 (**Fig. 3A and C**). The voltage sensor of domain IV is also known to be an important determinant of fast inactivation: its movement being a rate-limiting step for both development and recovery from fast inactivation.[13] The location of this variant is therefore also consistent with its functional effects and highlights the important role that this dynamic interface plays in the control of fast inactivation.

4. Discussion

The development of painful DPN is a complex multifactorial process that involves an interaction between the metabolic disturbances characteristic of diabetes mellitus, environmental factors, and genotype. In this study, we address the question of whether individual genetic variations in the $Na_V1.7$ could have an impact on the development of painful DPN. We screened for $Na_V1.7$ variants in a cohort of 189 study participants that comprised 111 with painful DPN and 78 with a painless DPN phenotype. Although no rare variants could be identified in the



Figure 2. Effect of M1852T and T1596I variants on the biophysical properties of $Na_V1.7$ channels. (A) Representative currents elicited from a holding potential of −100 mV to different test pulse potentials (50 ms) ranging from −80 to 40 mV in 5 mV increments, for the WT (black), M1852T (red), or T1596 (blue) channels. (B) Normalized peak current–voltage relationship curves from traces in panel A for the WT (black dots, $V_{1/2} = -29.9 \pm 1.3$, k = 5.7 ± 0.3, n = 19), M1852T (red squares, $V_{1/2} = -27.6 \pm 1.3$, k = 6.3 ± 0.5, n = 11), or T1596 (blue triangles, $V_{1/2} = -26.6 \pm 2.4$, k = 5.5 ± 0.6, n = 9) channels. (C) Steady-state fast inactivation curves for the WT (black dots, $V_{1/2} = -86.6 \pm 1.4$, k = 5.6 ± 0.2, n = 18), M1852T (red squares, $V_{1/2} = 72.5 \pm 3$, k = 9.1 ± 0.3, n = 11, $P \leq 0.0001$), or T1596 (blue triangles, $V_{1/2} = 71.2 \pm 2.2$, k = 7.6 ± 0.3, n = 9, $P \leq 0.0001$) channels. Currents were elicited with test pulses to −10 mV after 500 ms of inactivating prepulses. (D) Overlapping voltage dependence of steady-state activation and steady-state fast inactivation. The inset shows an enlargement of the overlapping area representing the window current for the WT (black), M1852T (red), and T1596I (blue) channels. (E) Steady-state slow inactivation curves for the WT (black dots, $V_{1/2} = -61.1 \pm 2.8$, k = 13.7 ± 0.5, n = 12), M1852T (red squares, $V_{1/2} = -67.5 \pm 3.8$, k = 12.9 ± 0.8, n = 8), or T1596 (blue triangles, $V_{1/2} = -60.9 \pm 2.4$, k = 11.7 ± 0.7, n = 9) channels. Currents were elicited with test pulses to −10 mV after 30 second of inactivating prepulses and a pulse to −120 mV to remove fast inactivation. (F) Open-state fast-inactivation kinetics for the WT (black dots, n = 19), M1852T (red squares, n = 11), or T1596 (blue triangles, n = 9) channels measured by fitting the current decay of the traces in A with a single exponential function. (G) Recovery from inactivation for the WT (black dots, $\tau = 102.3 \pm 16.7$, n = 14), M1852T (red squares, $\tau = 106.3 \pm 21.8$, n = 9), or T1596 (blue triangles, $\tau = 28.7 \pm 6.8$, n = 8) channels measured using two −10 mV test pulses lasting 20 ms applied from a holding potential of −100 mV and separated by increasing durations. (H) Mean ramp currents for the WT (black, n = 11), M1852T (red, n = 7), or T1596 (blue, n = 8) channels. The currents were evoked by depolarizing the membrane potential at a rate of 0.2 mV/ms from −100 to 0 mV. The response has been rescaled as the percentage of the maximal peak inward current obtained from traces in panel A. Data information: In (B–G), data are presented as mean ± SEM. Statistical analysis were performed using 1-way analysis of variance combined with Dunnett post hoc analysis for multiple comparisons. *P* values given compared with the WT. $V_{1/2}$ represents the half-activation and, respectively, half-inactivation potential, k, the slope factor.

painless group, we found a significant number (12) of rare $Na_V1.7$ variants in 10 participants from the painful DPN group. Functional characterization of 2 of these variants (M1852T and T1596I) demonstrated gain of function changes, consistent with an increase in neuronal excitability. This is the first study that has investigated the presence of rare $Na_V1.7$ variants in patients with painful DPN using a cohort in which detailed phenotyping was used to stratify patients according to the sensory profile.[28] The establishment of somatosensory phenotype allowed us to examine the differences between the 10 study participants



Figure 3. $Na_V1.7$ channel structural model. (A) Side view of the $Na_V1.7$ structural model showing the M1852 (magenta) and T1596 (yellow). (B) Enlargement of the region containing the M1852 residue; note the proximity to the III-IV linker. (C) Enlargement of the region containing T1596; note the proximity to the S6 of domain I. The transmembrane domains D I, D II, D III, and D IV are represented in dark blue, light blue, cyan, and aquamarine, respectively. The cytoplasmic linker III-IV (L III-IV) is in dark red and the C-terminal domain (CTD) in cream.

carrying rare $Na_V1.7$ variants and the rest of the painful DPN group. Three statistical significant differences were found: (1) the study participants carrying rare $Na_V1.7$ variants had been diagnosed for a significantly shorter duration (2) they reported more severe burning pain, and (3) they were more sensitive to deep pressure and reported pain at lower pressures when applied to the arch of the foot. The absence of a clearer phenotypic distinction between the 2 groups is similar to a study in which erythromelalgia patients carrying the pathogenic $Na_V1.7$ mutation I848T could not be phenotypically distinguished from those not carrying the mutation.[67] The addition of suprathreshold QST paradigms might improve our ability to differentiate mechanistically relevant subgroups.[32] Larger replication studies will be needed to determine whether these phenotypic aspects could be used in the future to stratify patients for potential genetic testing. This could be relevant to future treatment choices, given the major effort to develop selective small molecule blockers of $Na_V1.7$, some of which are currently in clinical trials.[66]

Among the 12 rare $Na_V1.7$ variants identified, 5 were already shown to be associated with painful related disorders: R185H, I739V, V991L, M932L, and W1538R. The first 4 (R185H, I739V, and V991L/M932L) were previously found in patients with idiopathic small fibre neuropathy.[30] The latter (W1538R) was identified in a patient with primary erythromelalgia.[16] One previous study also reported an association between the variants V991L/M932L (which are in complete linkage disequilibrium) and painful DPN vs population controls.[39] In contrast to Li et al., we used painless DPN as a control group rather than normal controls without diabetes because this is the most appropriate comparison to address the question as to which variants promote the development of NeuP in DPN. It has been hypothesised that because $Na_V1.7$ is expressed in pancreatic β cells, variants in this ion channel could confer vulnerability to injury.[33]

The comparison of the published clinical phenotypes of previously reported patients with $Na_V1.7$ variants with those from our cohort carrying the same variants revealed some differences. For instance, the I739V variant was described in patients with small fibre neuropathy and severe autonomic dysfunction.[29] However, in our study we did not elicit significant autonomic dysfunction from the affected study participant. The R185H variant was also previously found in patients with small fibre neuropathy but who had minimal autonomic dysfunction.[30] In our cohort, this variant was found in 2 patients one of who had a postural drop in blood pressure (suggesting sympathetic autonomic dysfunction) and one who did not. The patient from our study carrying the W1538R variant (described previously in a patient with primary erythromelalgia[16]) did not demonstrate erythromelalgia or changes in symptomology related to changes in temperature. These findings suggest that 1 variant can produce different clinical pain phenotypes, which will depend on the environmental context. For instance, in DPN the structural injury to autonomic axons as a consequence of diabetes will have a major impact on autonomic function independent of any direct effects of $Na_V1.7$ variants on autonomic neuron excitability.[30] In our cohort, none of the participants reported a family history, and only 1 participant reported symptoms that began before a diagnosis of diabetes was made. We therefore propose that these rare variants in $Na_V1.7$ may act as risk factors promoting the development of NeuP in the context of an environmental trigger (diabetes) rather than causing a Mendelian pain disorder.

Six of the 12 rare $Na_V1.7$ variants identified by this study (I564T, K655R, S802G, K1043N, T1596I, and M1852T) are new variants, not having been described in the literature in association with pain-related disorders. However, one of them, K655R, was reported in patients with febrile seizures.[54] In our case, the study participant carrying the K655R did not report a history of seizures.

An analysis of the unpublished variants using different pathogenic predictive algorithms pinpointed 2 of them (T1596I and M1852T) as highly likely to be pathogenic. Their electrophysiological analysis showed that these variants strongly affected the inactivation properties of the channel. Both T1596I and M1852T exhibited a strong shift (14-15 mV) of the steady-state fast inactivation curve towards more depolarised membrane potentials, increased window current, slower inactivation kinetics and, for the T1596I variant, a significant faster recovery from inactivation. All these changes are consistent with a gain of function of the channel, which would most likely lead to an increase in neuronal excitability thus contributing to pain signalling.

Our structural model reveals that the position of these mutations is consistent with its functional effects. Many previous structural models of $Na_V1.7$ have relied on comparison with the prokaryotic Na_V channels. However, we have been able to take advantage of the recent high-resolution cryoEM structure of a eukaryotic homologue, Na_VPS,[52] to construct an almost complete model of human $Na_V1.7$. In this model, M1852T is

located in the fifth alpha helix of the C-terminal domain, just below the III-IV linker, indicating possible interactions between this residue and the linker. As the III-IV linker is known to be a critical structural determinant of fast inactivation, the position of this variant is not only a structural basis of our electrophysiological findings but also highlights the dynamic role that this interface between the C-terminal domain and the III-IV linker may play in fast inactivation. Likewise, the position of the T1596I variant highlights an important functional role for the interface between the voltage sensor of domain IV and the pore-forming helices of domain I. Interestingly, mutation of a conserved glutamine situated at the top of S6 (Q270K) in domain I of $Na_V1.5$ also impairs fast inactivation.[12] This glutamine is predicted to be in close proximity to T1596 and therefore suggests an important and highly conserved role for this dynamic interface in the regulation of fast inactivation.

Compared with the other $Na_V1.7$ variants previously associated with painful neuropathies (such as small fibre neuropathy), T1596I and M1852T appear unique. Most of the described variants in idiopathic small fibre neuropathy have relatively mild effects on fast inactivation.[24] On the other hand, $Na_V1.7$ mutations, associated with PEPD, a severe pain condition characterised by episodic pain and flare response of the sacrum, periocular, and mandibular regions,[14,22,26,35,55,58] have much more profound effects on inactivation (V1298F, V1299F, I1461T, G1607R, L1612P, M1627K, and A1632E). Two of these mutations, G1607R and L1612P, are also located in S4 of domain IV with the others in the S4-S5 linker of domain III (V1298F and V1299F), S4-S5 linker of domain IV (M1627K and A1632E), or part of the IFM motif in linker III-IV (I1461T). However, the M1852T variant that we describe here is the first mutation in the C-terminal domain of $Na_V1.7$ reported to have a major effect on inactivation and may also provide evidence for a possible state-dependence of the interaction of the III-IV linker with the C-terminal domain during inactivation.

Although broad generalisations can be drawn when comparing the biophysical impact of $Na_V1.7$ variants with clinical phenotype (for instance that inherited erythromelalgia is associated with enhanced channel activation and PEPD with impaired channel inactivation), we still have an incomplete understanding of how channel dysfunction causes specific pain phenotypes. Certain $Na_V1.7$ variants have also been shown to cause the degeneration of DRG axons in vitro particularly under conditions of metabolic stress,[23,50] and so an interesting topic for future studies will be whether $Na_V1.7$ variants may not only impact on pain phenotype in DPN but also neuropathy progression.

In conclusion, this study reveals an important link between painful DPN and $Na_V1.7$, suggesting that rare $Na_V1.7$ variants may predispose patients with diabetic neuropathy to developing NeuP. Despite the challenges, prospective studies of diabetes and its complications would be very helpful in extending these findings. Better understanding of genetic variability in NeuP disorders combined with improved sensory phenotyping should also improve patient stratification for future clinical trials and help target therapy more appropriately.

Conflict of interest statement

A.S.C. Rice undertakes consultancy and advisory board work for Imperial College Consultants—in the past 36 months, this has included remunerated work for Spinifex, Abide, Astellas, Neusentis, Merck, Mitsubishi, Aquilas, Asahi Kasei, Galapagos, Toray, Quartet, Relmada, Novartis, and Orion. A.S.C. Rice was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued on the acquisition of Spinifex by Novartis in July 2015 and from which future milestone payments may occur. A.S.C. Rice is named as an inventor on patents: Rice A.S.C., Vandevoorde S., and Lambert D.M. Methods using N-(2-propenyl) hexadecanamide and related amides to relieve pain. WO 2005/079771; Okuse K. et al Methods of treating pain by inhibition of vgf activity EP13702262.0/WO2013 110945. D.L.H. Bennett has undertaken consultancy and advisory board work for Oxford innovation—in the past 36 months, this has included renumerated work for Abide, Biogen, GSK, Lilly, Mitsubishi Tanabe, Mundipharma, Teva, and Pfizer. D.L.H. Bennett is a Wellcome Senior Clinical Scientist (202747/Z/16/Z). D.L.H. Bennett and S.J. Tucker are members of the Wellcome Trust funded OXION Initiative (WT084655MA). The remaining authors have no conflicts of interest to declare.

Supported by the Wellcome Trust through a Strategic Award to the London Pain Consortium (ref. no. 083259). D.L.H. Bennett, I. Blesneac, and A.C. Themistocleous are members of the DOLORisk Consortium funded by the European Commission Horizon 2020 (ID633491). D.L.H. Bennett and A.C. Themistocleous are members of the International Diabetic Neuropathy Consortium, the Novo Nordisk Foundation, grant number NNF14SA0006. A.C. Themistocleous is an Honorary Research Fellow of the Brain Function Research Group, School of Physiology, Faculty of Health Science, University of the Witwatersrand. J.J. Cox is funded by the MRC (G1100340) and the Wellcome Trust (200183/Z/15/Z).

Acknowledgements

The authors thank all patients and healthy volunteers for their participation.

Appendix A. Supplemental digital content

Supplemental digital content associated with this article can be found online at http://links.lww.com/PAIN/A508, http://links.lww.com/PAIN/A509.

Supplemental video content

Video content associated with this article can be found online at http://links.lww.com/PAIN/A510.

Article history:
Received 31 July 2017
Received in revised form 20 September 2017
Accepted 11 October 2017
Available online 22 November 2017

References

[1] Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.
[2] Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–4.
[3] Armougom F, Moretti S, Poirot O, Audic S, Dumas P, Schaeli B, Keduas V, Notredame C. Expresso: automatic incorporation of structural information in multiple sequence alignments using 3D-Coffee. Nucleic Acids Res 2006;34:W604–8.
[4] Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11:999–1005.
[5] Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, Finnerup NB, Haanpaa M, Hansson P, Hullemann P, Jensen TS, Freynhagen R,

Kennedy JD, Magerl W, Mainka T, Reimer M, Rice AS, Segerdahl M, Serra J, Sindrup S, Sommer C, Tolle T, Vollert J, Treede RD. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. PAIN 2017;158:261–72.
[6] Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol 2014;13:587–99.
[7] Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). PAIN 2005;114:29–36.
[8] Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the neuropathic pain symptom inventory. PAIN 2004; 108:248–57.
[9] Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS One 2013;8:e74195.
[10] Bril V, Perkins BA. Validation of the Toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care 2002;25:2048–52.
[11] Buschbacher R, Orahlow N. Manual of nerve conduction studies. New York: Demos Medical Publishing, 2006.
[12] Calloe K, Schmitt N, Grubb S, Pfeiffer R, David JP, Kanter R, Cordeiro JM, Antzelevitch C. Multiple arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A. Can J Physiol Pharmacol 2011;89:723–36.
[13] Capes DL, Goldschen-Ohm MP, Arcisio-Miranda M, Bezanilla F, Chanda B. Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. J Gen Physiol 2013;142:101–12.
[14] Choi JS, Boralevi F, Brissaud O, Sanchez-Martin J, Te Morsche RH, Dib-Hajj SD, Drenth JP, Waxman SG. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons. Nat Rev Neurol 2011;7:51–5.
[15] Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006;444:894–8.
[16] Cregg R, Laguda B, Werdehausen R, Cox JJ, Linley JE, Ramirez JD, Bodi I, Markiewicz M, Howell KJ, Chen YC, Agnew K, Houlden H, Lunn MP, Bennett DL, Wood JN, Kinali M. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia. Neuromolecular Med 2013;15:265–78.
[17] Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 1998;18:9607–19.
[18] Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. PAIN 2014;155:2263–73.
[19] Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang JM, Taly JF, Notredame C. T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res 2011;39:W13–7.
[20] Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013;14:49–62.
[21] England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64:199–207.
[22] Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG. Nav1.7 gain-of-function mutations as a continuum: a1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci 2008;28:11079–88.
[23] Estacion M, Vohra BP, Liu S, Hoeijmakers J, Faber CG, Merkies IS, Lauria G, Black JA, Waxman SG. Ca2+ toxicity due to reverse Na+/Ca2+ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation. J Neurophysiol 2015;114:1554–64.
[24] Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G, Vanhoutte EK, Gerrits MM, Dib-Hajj S, Drenth JP, Waxman SG, Merkies IS. Gain of function Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012;71:26–39.
[25] Feldman EL, Nave KA, Jensen TS, Bennett DL. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron 2017;93: 1296–313.
[26] Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767–74.
[27] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–73.
[28] Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. PAIN 2016; 157:1599–606.
[29] Han C, Hoeijmakers JG, Ahn HS, Zhao P, Shah P, Lauria G, Gerrits MM, te Morsche RH, Dib-Hajj SD, Drenth JP, Faber CG, Merkies IS, Waxman SG. Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. Neurology 2012;78:1635–43.
[30] Han C, Hoeijmakers JG, Liu S, Gerrits MM, te Morsche RH, Lauria G, Dib-Hajj SD, Drenth JP, Faber CG, Merkies IS, Waxman SG. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain 2012;135:2613–28.
[31] Hebert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. PAIN 2017;158:560–8.
[32] Helas T, Sagafos D, Kleggetveit IP, Quiding H, Jonsson B, Segerdahl M, Zhang Z, Salter H, Schmelz M, Jorum E. Pain thresholds, supra-threshold pain and lidocaine sensitivity in patients with erythromelalgia, including the I848T mutation in NaV 1.7. Eur J Pain 2017;21:1316–25.
[33] Hoeijmakers JG, Faber CG, Merkies IS, Waxman SG. Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point? Trends Mol Med 2014;20:544–50.
[34] Huang J, Han C, Estacion M, Vasylyev D, Hoeijmakers JG, Gerrits MM, Tyrrell L, Lauria G, Faber CG, Dib-Hajj SD, Merkies IS, Waxman SG, Group PS. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain 2014;137:1627–42.
[35] Jarecki BW, Sheets PL, Jackson JO II, Cummins TR. Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. J Physiol 2008;586:4137–53.
[36] Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103–9.
[37] Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies ISJ, Polydefkis M, Smith AG, Sommer C, Valls-Solé J. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010;17:79–92.
[38] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754–60.
[39] Li QS, Cheng P, Favis R, Wickenden A, Romano G, Wang H. SCN9A variants may be implicated in neuropathic pain associated with diabetic peripheral neuropathy and pain severity. Clin J Pain 2015;31:976–82.
[40] Magerl W, Krumova EK, Baron R, Tölle T, Treede R-D, Maier C. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. PAIN 2010; 151:598–605.
[41] Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000;29:291–325.
[42] Medical Research Council—Nerve Injuries Research Committee. Aids to the examination of the peripheral nervous system: Saunders Elsevier on behalf of Guarantors of Brain. Philadelphia, PA: Elsevier, 2010.
[43] Notredame C, Higgins DG, Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol 2000;302:205–17.
[44] O'Sullivan O, Suhre K, Abergel C, Higgins DG, Notredame C. 3DCoffee: combining protein sequences and structures within multiple sequence alignments. J Mol Biol 2004;340:385–95.
[45] Poirot O, Suhre K, Abergel C, O'Toole E, Notredame C. 3DCoffee@igs: a web server for combining sequences and structures into a multiple sequence alignment. Nucleic Acids Res 2004;32:W37–40.
[46] Reimann F, Cox JJ, Belfer I, Diatchenko L, Zaykin DV, McHale DP, Drenth JP, Dai F, Wheeler J, Sanders F, Wood L, Wu TX, Karppinen J, Nikolajsen L, Mannikko M, Max MB, Kiselycznyk C, Poddar M, Te Morsche RH, Smith S, Gibson D, Kelempisioti A, Maixner W, Gribble FM, Woods CG. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A 2010;107:5148–53.

[47] Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRF, Consortium WGS, Wilkie AOM, McVean G, Lunter G. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet 2014;46:912–8.
[48] Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Botefur IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihofner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. PAIN 2006;123:231–43.
[49] Rolke R, Magerl W, Campbell K, Schalber C, Caspari S, Birklein F, Treede R. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 2006;10:77–88.
[50] Rolyan H, Liu S, Hoeijmakers JG, Faber CG, Merkies IS, Lauria G, Black JA, Waxman SG. A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration of small-diameter axons associated with intracellular Ca2+ dysregulation and decrease in ATP. Levels Mol Pain 2016;12.
[51] Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779–815.
[52] Shen H, Zhou Q, Pan X, Li Z, Wu J, Yan N. Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. Science 2017;355.
[53] Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci 2006;15:2507–24.
[54] Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe P, Thompson J, Dixon M, Gurnett C, Peiffer A, White HS, Filloux F, Leppert MF. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 2009;5: e1000649.
[55] Suter MR, Bhuiyan ZA, Laedermann CJ, Kuntzer T, Schaller M, Stauffacher MW, Roulet E, Abriel H, Decosterd I, Wider C. p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder. Anesthesiology 2015;122: 414–23.
[56] Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133–7.
[57] Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Group TDNE, Albers JW, Amarenco G, Anderson H, Arezzo J, Backonja MM, Biessels GJ, Bril V, Cameron N, Cotter M, England J, Feldman E, Frontoni S, Hilsted J, Low P, Malik RA, O'Brien PC, Pop-Busui R, Perkins B, Rayman G, Russell J, Sindrup S, Smith G, Stevens M, Várkonyi T, Veves A, Vileikyte L, Ziegler D, Zochodne D, Jones T. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–93.
[58] Theile JW, Jarecki BW, Piekarz AD, Cummins TR. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. J Physiol 2011;589:597–608.
[59] Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, Tesfaye S, Rice AS, Bennett DL. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. PAIN 2016;157:1132–45.
[60] Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206–13.
[61] Wang C, Chung BC, Yan H, Lee SY, Pitt GS. Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. Structure 2012;20:1167–76.
[62] Waxman SG, Merkies IS, Gerrits MM, Dib-Hajj SD, Lauria G, Cox JJ, Wood JN, Woods CG, Drenth JP, Faber CG. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol 2014;13:1152–60.
[63] Webb B, Sali A. Comparative protein structure modeling using modeller. Curr Protoc Bioinformatics 2014;47:5.6.1–32.
[64] Yan Z, Zhou Q, Wang L, Wu J, Zhao Y, Huang G, Peng W, Shen H, Lei J, Yan N. Structure of the Nav1.4-beta1 complex from electric Eel. Cell 2017;170:470–82.e11.
[65] Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, Fan J, Bu D, Liu B, Fan Z, Wu G, Jin J, Ding B, Zhu X, Shen Y. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004;41:171–4.
[66] Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; Study investigators. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol 2017;16:291–300.
[67] Zhang Z, Schmelz M, Segerdahl M, Quiding H, Centerholt C, Juréus A, Carr TH, Whiteley J, Salter H, Kvernebo MS, Ørstavik K, Helås T, Kleggetveit I-P, Lunden LK, Jørum E. Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia. Scand J Pain 2014;5:217–25.
[68] Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, Feldman EL, Alexander NB, Russell JW. Assessing autonomic dysfunction in early diabetic neuropathy: the survey of autonomic symptoms. Neurology 2011;76:1099–105.

	Painful diabetic neuropathy	Painless diabetic neuropathy
Number	111	78
Male	77 (69.4%)	55 (70.5%)
Age (years)	66.6 (57.2-72.3)	68.6 (60.9-73.6)
HbA1c (%)	7.7 (6.8-8.9)	7.3 (6.5-8.0) *
Type 2 diabetes	99 (89.2%)	74 (94.9%)
Duration of diabetes (years)	14.1 (7.9-21.3)	13.9 (9.8-20.9)
BMI (kg/m^2)	30.5 (26.8 – 36.0)	29.8 (25.9-34.4)
Standing BP	141/78 (128/67-152/85)	145/81 (130/71-156/88)
Lying BP	146/78 (134/71-156/85)	146/80 (131/71-154/86)
Orthostatic hypotension	27 (28%)	13 (17.8%)
MRC sensory sum score	7 (3-12)	4 (2-8) †
TCSS Total (adjusted)	11 (8-13)	8 (5-10) †
TCSS Symptoms score (adjusted)	3 (2-4)	1 (1-2) †
TCSS Sensory examination	4 (2-5)	2 (1-4) †
TCSS Examination	8 (6-10)	7 (4-9) †
IENFD (fibres/mm)	0.8 (0.3-1.6)	1.2 (0.4-1.9)
Pain over last 24 hours	6 (4-8)	N/A
Seven day pain diary	5 (3.2-6.9)	N/A
DN4	6 (4-7)	2 (1-3) †

Table S1. Summary of variables that were compared between the study participants with painless and painful diabetic peripheral neuropathy

Data shown as median (interquartile range) and analysed by Mann-Whitney U Test. Categorical data were analysed by Fischer's exact test, and values and percentages are shown.Symbols reflect the differences between the respective groups: †- P < 0.01; *- P < 0.05

BMI – Body Mass Index; BP - Blood pressure; TCSS – Toronto Clinical Scoring System; MRC- Medical Research Council; IENFD- Intra-epidermal nerve fibre density; IENFD – Intra-epidermal nerve fibre density

	Homozygous		Heterozygous				
	W1150R	M1713V	P610W	S490N	R1110Q	W1150R	N1245S
Painless DPN	56	0	5	1	1	21	1
Painful DPN	78	4	2	4	5	33	3

Table S2. Common Nav1.7 variants identified

Summary of the nonsynonymous substitution that have a frequency in population databases higher than 1%. The numbers indicate how many study participants from each group were found to carry these variant. Fisher test was used to examine a possible statistical difference between groups.


Diabetes mellitus
N =8 - No neuropathy
N=7 - Possible clinical neuropathy but no abnormality on investigations
N=10 – Blood not available
No
N = 214
Possible clinical neuropathy
AND
Abnormalities on either
Nerve Conduction Studies OR Intra-Epidermal Nerve Fibre Density
Yes
Definite Diabetic Peripheral Neuropathy
Definite chronic neuropathic pain:
IASP definition & NeupSIG grading system
-'pain caused by a lesion or disease of the somatosensory system' for longer than three months
N = 189
No
Yes
N = 78
N = 111
Painless diabetic neuropathy
Painful diabetic neuropathy
Sequencing of Nav 1.7 sodium channel
Rare variants of Nav 1.7 sodium channel
No
Yes
N = 78 - Painless diabetic neuropathy
N = 101 - Painful diabetic neuropathy
N = 10 - Painful diabetic neuropathy

Figure S1


DFNS Z-score
4
2
0
-2
-4
-6
-8
*
**
*
**
Painless diabetic neuropathy
Painful diabetic neuropathy
Nav 1.7 rare variant
CDT
WDT
TSL
CPT
HPT
MDT
VDT
MPT
MPS
WUR
PPT

Figure S2